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activity3,4 in heart-lung or double-lung transplant recip-
ients have been previously demonstrated. In all of these
studies, donor peripheral blood lymphocyte (PBL) or
lymphoblastoid cells have been used as stimulator cells.
Because the lung epithelium is one of the first tissues
D onor-specific cytotoxic T lymphocytes (CTL) areconsidered to play an important role in acute allo-
graft rejection by virtue of their direct cytotoxicity
against the graft parenchymal cells. A primed lympho-
cyte test (PLT) response1,2 and donor-specific CTL
Background: The lung epithelium is among the first donor tissues encoun-
tered by the lung allograft recipient’s immune system. The purpose of
this study was to determine whether lung epithelium was recognized by
T lymphocytes that are isolated from bronchoalveolar lavage fluid of
lung allograft recipients during periods of acute rejection. Methods:
Lymphocytes isolated from 45 bronchoalveolar lavage samples (from 41
lung transplant recipients) served as effector cells in standard cell-medi-
ated cytolytic assays with several cell lines as targets: BEAS-2B (an
immortalized airway epithelial cell line); B-lymphoblastoid cell lines;
and K562 (a natural killer–sensitive cell line). Cytotoxic T-lymphocyte
activity of bronchoalveolar lavage lymphocytes was correlated with
pathologic status. Results: During acute rejection alone (ie, without con-
comitant cytomegalovirus infection), mean lysis of the airway epithelial
target was significantly greater, compared with during no rejection,
when these targets expressed donor-specific HLA class I antigens (P =
.007). Lysis of donor class I–matched B-lymphoblastoid cell line targets
during rejection was not significantly different from lysis during no-
rejection periods (P = .18). Mean lysis of K562, a natural killer cell tar-
get, did not differ between acute rejection (without concomitant
cytomegalovirus infection) and no rejection (P = .30). During
cytomegalovirus infection (without concomitant acute rejection), there
was no difference in mean lysis of airway epithelial cells, B-lymphoblas-
toid cell lines, or K562 targets compared with during no
cytomegalovirus infection, whereas during acute rejection, compared
with cytomegalovirus infection without rejection, there was a significant
increase in mean lysis of the airway epithelial target when it expressed
donor-specific HLA antigens (P = .01). Conclusions: Donor HLA class
I–specific cytotoxic T-lymphocyte activity directed at airway epithelial
cells was demonstrated in bronchoalveolar lavage lymphocytes from
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encountered by the recipient’s immune system, we
hypothesized that these cells should be the target of
recipient cells in in vitro assays. The purpose of this
study was to demonstrate the presence of donor major
histocompatibility complex (MHC) directed CTL in
bronchoalveolar lavage (BAL) fluid lymphocyte popu-
lations of lung transplant recipients, to determine
whether these cells were reactive with airway epithelial
cells expressing donor mismatched class I molecules,
and to correlate this reactivity with the occurrence of
acute rejection. We hypothesize that, as the recipient’s
lymphocytes undergo allosensitization to parenchymal
cells of the donor lung,5,6 the resultant alloreactive CTL
should exhibit cytotoxicity against donor MHC-
matched target cell lines, specifically bronchial epithe-
lial cells.
Patients and methods
General. This study was conducted under full institutional
review board approval, and all patients signed an informed
consent form acknowledging their participation before entry.
Forty-five BAL fluid samples were obtained from 41 lung
transplant recipients for this study. HLA phenotypes of the
lung transplant recipients and their respective donors were
determined with the microcytotoxicity technique7 in the HLA
laboratory at Barnes-Jewish Hospital. All of the transplanta-
tions were carried out with negative cross match (in retro-
spect), and no attempt was made to achieve prospectively an
HLA match between donors and recipients. Because the main
objective of the study was to demonstrate class I–directed
CTL activity of BAL lymphocytes during acute rejection,
BAL samples were obtained, whenever possible, from recip-
ients such that at least one of their sensitizing donor alloanti-
gens was represented in the panel of targets.
Immunosuppression. The immunosuppression regimen
has been described elsewhere in greater detail.8 In brief, the
induction regimen consisted of cyclosporine (INN:
ciclosporin), azathioprine, and antithymocyte globulin (since
1992) followed by a maintenance regimen of cyclosporine,
azathioprine, and prednisone. Steroids were given in the fol-
lowing manner: methylprednisolone 1 g intravenously before
reperfusion, then 0.5 mg/kg intravenously daily, and convert
to oral prednisone 0.5 mg/kg daily, tapered gradually to
approximately 15 mg orally daily at 1 year.
Follow-up bronchoscopy after transplantation. Recip-
ient follow-up included interval chest radiographs, arterial
blood gases, pulmonary function testing, and fiberoptic bron-
choscopy. BAL and transbronchial lung biopsy (TBLB) were
performed (by fiberoptic bronchoscopy) routinely at 1, 3, 6,
and 12 months after transplantation then annually thereafter.
Additional BAL and TBLB were carried out when there was
clinical suspicion of rejection or infection. The bronchoscop-
ic procedure has been previously described.8 Lavage fluid
was submitted for routine clinical tests, and a small leftover
aliquot was provided for this study.
Pathologic diagnosis. TBLB tissue was fixed in formalde-
hyde solution and stained with hematoxylin and eosin to
allow histologic analysis. 
Diagnosis of acute rejection. Pathologic findings from
TBLB were used to confirm the presence and grade of acute
rejection. In brief, the grade of rejection was histologically
classified according to the working formulation for the stan-
dardization of terminology in heart and lung allograft rejec-
tion set forth by the Lung Rejection Study Group9 and graded
from A0 to A4.
Diagnosis of cytomegalovirus infection. Cytomegalovirus
pneumonitis was identified histologically by characteristic
intracellular inclusions on the hematoxylin and eosin stain or
by a positive immunoperoxidase stain. 
Cell-mediated lymphocytolysis assay
BAL lymphocyte preparation. Lymphocytes were isolated
from BAL fluid and used as effector cells in standard cell-
mediated lymphocytolysis (CML) assays. BAL fluid was fil-
tered through 4 layers of surgical gauze and centrifuged at
300g for 12 minutes. The sediments were washed twice in
phosphate-buffered saline solution and resuspended in 5 mL
of culture medium consisting of RPMI-1640 (Gibco BRL,
Gaithersburg, Md), 15% heat-inactivated human serum
(MLC Normal Serum Male Non AB plasma; RJO Bio-
logicals Inc, Kansas City, Mo), 5 mmol/L L-glutamine, 25
mmol/L HEPES buffer, and 100 m g/mL streptomycin and
100 U/mL penicillin. Macrophages were removed by magnet
sedimentation after a brief incubation with carbonyl iron.
The remaining lymphocytes were purified by Ficoll-
Hypaque density gradient sedimentation. In general, the vol-
ume of BAL obtained from the patient was about 100 mL
(range, 60-110 mL). The lymphocyte yield was typically
about 1.0 to 2.0 · 106 cells per 100 mL of BAL (range, 0.2-
7.1 · 106 cells). 
Target cell lines. The cell lines used included BEAS-2B (an
immortalized airway epithelial cell line, which was provided
by Dr Curtis Harris10; VAVY, EAG254, and EBZ369 (Epstein
Barr virus-transformed B-lymphoblastoid cell lines); and the
natural killer–sensitive cell line, K562.11 The HLA pheno-
types of BEAS-2B and the lymphoblastoid cell lines were
determined by the HLA laboratory at Barnes-Jewish Hospital
(Table I). For this study, HLA-A and B were considered rep-
resentative of class I, and HLA-DR was considered represen-
tative of class II. These cell lines were selected on the basis
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Table I. Targets used in CTL analysis
Cell line Type HLA
BEAS-2B AECL A2,28;B45,60;DR2,3
VAVY LCL* A1,—;B8,—;DR3,—
EAG254 LCL A3,24;B7,62;DR2,4
EBZ369 LCL A2,—;B7,44;DR4,15
K562 NK sensitive HLA negative
AECL, SV40–transfected airway epithelial cell line10; LCL, lymphoblastoid
cell lines; NK, natural killer.
*Epstein Barr–transformed B-lymphoblastoid cell line.
of their HLA phenotypes, specifically because they expressed
common HLA class I antigens. For example, considering
only the HLA-A locus, our 3 lymphoblastoid cell lines
expressed HLA-A1, A2, A3, and A24 (Table I). By including
the BEAS-2B target, HLA-A28 was also expressed. The pre-
dicted frequencies of these 5 alleles in the white population
are 28.6%, 45.8%, 20.6%, 16.8%, and 8.8%, respectively.12
We therefore thought it likely that these targets would share
some mismatched (or “sensitizing”) donor HLA class I anti-
gens in a substantial number of the experiments. 
In summary, in each CML assay, there were 5 targets: 4 tar-
gets with MHC expression (3 lymphoblastoid cell lines and
BEAS-2B) and K562, which lacks MHC expression.
Determination of target lysis. CTL analysis was performed
with a standard chromium-51 release assay, as previously
described.13 In brief, 0.5 · 106 cells serving as targets were
labeled with 125 m Ci of 51Cr (ICN, Costa Mesa, Calif) for 60
minutes at 37°C. After extensive washing, 2500 targets in 0.1
mL culture medium were transferred to wells of 96-well U-
bottomed plates. BAL lymphocytes in 0.1 mL culture medi-
um were co-cultured with 51Cr-labeled target cells for 4 hours
at 37°C. The yield of lymphocytes from BAL fluid usually
gave an effector-to-target ratio between 10:1 and 20:1 (range,
6:1-40:1). After a 4-hour incubation, culture supernatants
were harvested and counted with a gamma counter
(Pharmacia LKB Biotechnology, Uppsala, Sweden). 
Data analysis
Pathologic diagnosis. In each CML assay, the pathologic
diagnosis was determined from the TBLB obtained simulta-
neously. We sought the following histologic states, as they
defined the 3 study groups: quiescent (REJ–; ie, implying no
rejection or cytomegalovirus infection); acute rejection alone
(REJ+; ie, without concomitant cytomegalovirus infection);
and cytomegalovirus infection alone (cytomegalovirus+; ie,
without concomitant acute rejection). 
Mean lysis values and statistical comparisons. Mean (±
SEM) values of target lysis were compared for each target
(BEAS-2B, lymphoblastoid cell lines, K562) between the
following groups: quiescent versus acute rejection; quiescent
versus cytomegalovirus infection; and acute rejection versus
cytomegalovirus infection. T test with Dunn-Sidak adjusted
probabilities and analysis of variance with Tukey’s multiple
comparisons test were used to determine whether there were
significant differences between mean values.
Subgrouping of lysis data for the comparison of quiescent
versus acute rejection. For comparison between quiescent
versus acute rejection, the mean values for target lysis were
subgrouped as Cl I+ or Cl II+ and Cl-, respectively, to deter-
mine the effect of MHC restriction on the lysis. This was
accomplished as follows: each CML assay yielded a lysis
value for the 5 targets. For those targets with MHC expres-
sion (BEAS-2B and the 3 lymphoblastoid cell lines), the tar-
get could be categorized as Cl I+ or Cl II+, if it shared a mis-
matched class I or II antigen with that recipient’s donor, or as
Cl-, if it lacked entirely any mismatched donor class I or II
antigens. 
Mean values for K562 lysis cannot be subgrouped this way
because this cell line lacks MHC expression. For the com-
parison between the cytomegalovirus+ versus quiescent and
cytomegalovirus+ versus REJ+ groups, the mean values for
target lysis were subgrouped as Cl+, if they shared a mis-
matched class I or II antigen with that recipient’s donor. Class
I and II were not separated because of the small numbers of
CML assays conducted on cytomegalovirus+ recipients (Fig 1).
Results
General. The bronchoscopies providing samples for
this study were conducted at a mean interval of 10.5
months after transplantation (range, 1-36 months).
Pathologic status and distribution of Cl I+, Cl II+,
and Cl– targets. Pathologic status of the recipients is
summarized in Table II. There were 18 patients in the
quiescent group (no rejection or cytomegalovirus infec-
tion); 20 patients in the REJ+ group (acute rejection
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Fig 1. CTL activity of BAL lymphocytes from patients with
cytomegalovirus infection and no rejection (cytomegalo-
virus+; n = 7 patients) are compared with quiescent patients
(no rejection or cytomegalovirus infection; n = 18 patients)
and patients with acute rejection and no cytomegalovirus
infection (REJ+; n = 20 patients). All values represent mean ±
standard error of the mean. 
Table II. Pathologic status of patients who have
received lung transplants
No. of assays with 
MHC+ (relevant)
Assays or MHC- (irrelevant) 
Pathologic diagnosis (n) targets (%)
Quiescent (REJ–) 18 15 (83)
Rejection (REJ+) 20 17 (85)
Cytomegalovirus infection 7 7 (100)
(cytomegalovirus+)
without cytomegalovirus infection); and 6 patients in
the cytomegalovirus+ group (cytomegalovirus infection
without rejection). In 15 of the 18 assays (83%) in the
quiescent group at least 1 target of those tested shared
mismatched donor class I or II antigens. In 17 of the 20
assays (85%) in the acute rejection group, at least 1 tar-
get shared mismatched donor class I or II antigens.
Finally, in 7 of the 7 assays (100%) in the cyto-
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Fig 2. Examples of lysis data from CML assays. BAL lymphocytes (A) were used at several effector-to-target
ratios (E:T) for 1 “Cl I+” lymphoblastoid cell line target and at a single E:T ratio for a “Cl-” target. Cl I+ target
has at least 1 mismatched donor class I antigen; Cl- target lacks any mismatched donor class I or II antigens. B
and C, HLA class I (HLA-A,B) and class II (HLA-DR) phenotypes of recipient and donor that pertain to two
assays from the acute rejection group are shown. The recipient (B) was exposed to alloantigens HLA-A29 and
B44, or HLA-A28 in C. Phenotypes of the targets used are shown in Table I.
megalovirus+ group, at least 1 target shared mis-
matched donor class I or II antigens.
Allospecific CTL activity. Before embarking on this
study, several preliminary CML assays were performed
to evaluate its feasibility. In these assays, BAL lym-
phocytes were obtained from recipients proved to be
undergoing acute rejection, and only 2 targets were
used in the panel: 1 Cl I+ lymphoblastoid cell lines tar-
get (ie, lymphoblastoid cell lines containing at least 1
mismatched donor class I antigen) and 1 Cl– lym-
phoblastoid cell lines target (ie, no mismatched donor
class I or II antigen shared by the lymphoblastoid cell
lines). Data from 1 such assay (Fig 2, A) shows specific
lysis of the Cl I+ target; the Cl– target was not lysed by
the BAL T cells. This effect was titratable (ie, depen-
dent on the effector to target ratio). These results indi-
cate that the lysis represents allospecific CTL activity. 
Because preliminary experiments demonstrated the
feasibility of the assays, the study was undertaken with
the full panel of 5 targets in each case. Illustrative CML
data from 2 recipients with acute rejection but no
cytomegalovirus infection are shown in Fig 2, B and C,
respectively. In each case, BAL lymphocytes lysed the
Cl I+ target at least twice as much as any of the Cl- tar-
gets. In 1 of the 2 patients (Fig 2, C), the airway epithe-
lial cell BEAS-2B was lysed. This again demonstrates
CTL activity directed at targets bearing donor MHC
class I alloantigens.
Relationship between CTL activity, acute rejec-
tion, and MHC class I and II antigens. Mean percent
lysis (± SEM) of BEAS-2B, lymphoblastoid cell lines,
and K562 targets was compared between the acute
rejection (REJ+) versus quiescent (no rejection [REJ–])
groups (Fig 3). For the BEAS-2B target, mean lysis
was significantly greater during rejection compared
with no rejection when the target expressed donor class
I alloantigens (11.1% ± 1.9% [n = 9] vs 2.1% ± 1.2%
[n = 4]; P = .007). A difference was noted between
rejection and no-rejection groups when the BEAS-2B
target expressed class II donor alloantigens (15.3% ±
3.9% [n = 7] vs 5.0% ± 1.8% [n = 7]; P = .09) and even
when BEAS-2B did not share any donor class I or II
allo-antigens (13.6% ± 4.5% [n = 8] vs 2.3% ± 0.7% [n
= 7]; P = .09). When Cl I+ lymphoblastoid cell lines tar-
gets were tested even when they expressed donor
alloantigens the lysis during rejection was not signifi-
cantly greater than the no-rejection group (8.2% ±
2.5% [n = 24] vs 3.0% ± 0.9% [n = 21]; P = .18 ). Mean
lysis did not differ between rejection and no-rejection
groups for any of the other targets including Cl II+
lymphoblastoid cell lines (P = .30), Cl– lymphoblastoid
cell lines targets (P = .58), or K562 targets (P = .30). 
In summary, there was greater lysis of the airway
epithelial target during acute rejection when this target
shared 1 or more donor class I (sensitizing) alloanti-
gens. However, there was also greater lysis of the air-
way epithelial targets, although not statistically greater,
during acute rejection even when these did not share
any sensitizing donor class I alloantigens. 
Relationship between cytotoxicity and cytomeg-
alovirus infection. To determine whether cytomegalo-
virus infection had any effect on donor-specific
responses, we looked at target lysis in patient samples
identified as cytomegalovirus positive. For this analysis
we compared the lysis of targets that expressed donor
mismatched MHC class I and II antigens together
(Cl+). When the mean percent lysis of the BEAS-2B,
lymphoblastoid cell lines, and K562 targets were com-
pared with the use of a 3-way analysis of variance
between the quiescent versus cytomegalovirus+ versus
acute rejection, a significant difference in mean lysis
was noted only between the acute rejection group and
the cytomegalovirus+ group when the airway epithelial
cell expressing donor mismatched MHC class I or II
antigens was used as a target (12.8% ± 2.6% [n = 12]
vs 5.68% ± 1.0% [n = 5]; P = .012).
Discussion
Our data demonstrate the presence of donor MHC
class I–directed airway epithelial cell CTL activity in
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Fig 3. CTL activity of BAL lymphocytes from patients who
underwent acute rejection alone (REJ+) compared with the
quiescent patients (REJ-). Cl I+ and Cl II+ targets express at
least 1 mismatched donor antigen. Cl- targets lack any donor
mismatched antigens. The number of patients in each target
group range from 3 to 23, depending on the number of donor-
matched antigens on each of the 4 targets used in each assay.
All values represent mean ± standard error of the mean. 
the BAL lymphocyte population from patients with
lung transplants during acute rejection. A number of
previous studies have reported on the behavior of BAL
lymphocytes isolated from pulmonary allografts, both
experimentally4 and clinically.1-3 BAL, being a rela-
tively noninvasive means of sampling the cellular and
soluble components of the airways, logically has been
used to study the cellular immune processes related to
pulmonary allograft rejection. Donor antigen-specific
PLT alloreactivity of BAL lymphocytes has been
shown to correlate with both acute rejection1 and post-
transplantation obliterative bronchiolitis.2 Rabinowich
and coworkers3 isolated lymphocytes from TBLB tis-
sue fragments, cultured them in media containing inter-
leukin-2, and showed that these tissue-infiltrating lym-
phocytes and BAL lymphocytes demonstrated
allospecific cytotoxicity in acute rejection and oblitera-
tive bronchiolitis. These findings suggested that the
behavior of BAL lymphocytes correlate well with the
in situ immune status of the allograft.3 Reinsmoen and
colleagues14 used a panel of homozygous typing cells
of known HLA antigens to further characterize the
class I or II restriction of the PLT response and report-
ed a predominantly class II–directed PLT response in
acute rejection and a predominantly class I–directed
pattern of PLT response in obliterative bronchiolitis.14
Thus there is strong evidence that a PLT alloprolifera-
tive response, analogous to a secondary mixed leuko-
cyte reaction, is demonstrable in acutely rejecting lung
allografts, implying the presence of activated T cells in
the graft.
Unlike the previously mentioned studies that have
focused on the proliferative response of graft-derived
lymphocytes to donor antigens, our study attempted to
evaluate the immune status of the graft through demon-
stration of donor antigen–specific cytotoxicity with
CML assays with BAL lymphocytes, specifically
examining the activity against an airway epithelial cell.
Our demonstration of increased lysis of donor class
I–relevant targets during rejection strongly suggests the
presence of allospecific CTL in lung allografts during
rejection. Recognizing the importance of the role of
CTLs in acute cellular allograft rejection, our study
would appear to most directly demonstrate ongoing
rejection in vivo that is targeted to the epithelium. 
A unique feature of our study was that we used an
airway epithelial cell line, BEAS-2B, as a target in the
panel. There was significantly greater lysis of BEAS-
2B during acute rejection compared with the “quies-
cent” state. However, unlike the lymphoblastoid cell
line targets, against which the slight increase in cyto-
toxicity during rejection was confined to donor class
I–relevant targets, an increased lysis of BEAS-2B
occurred regardless of whether or not BEAS-2B shared
any class I or II antigens with the donor. But, the
increased lysis reached significant levels (P = .007)
only when the BEAS-2B target expressed the donor
class I alloantigen. Hadley and colleagues15 previously
reported on clones of human CTL that exhibit class I
allospecificity in a kidney tissue–restricted manner,
with an in vitro mixed leukocyte-kidney culture sys-
tem. The basis for the tissue specificity displayed by
those clones was shown to be tissue-specific peptides
presented in the context of allo-class I.16 Our finding of
elevated CTL activity against BEAS-2B during rejec-
tion raises the possibility that the CTL recognizes a
unique bronchial epithelial antigen presented in the con-
text of MHC class I. This hypothesis can be tested only
when cloned T cells are available. We are currently con-
ducting further investigation to answer this question.
Cytomegalovirus infection and acute rejection can
share similar clinical presentations in patients with
lung transplants. Previous investigators have used pro-
liferative assays to identify cytomegalovirus infection
in lung allografts. These investigators have made corre-
lations between cytomegalovirus infection and BAL
lymphocyte proliferation in response to cytomegalo-
virus antigens,17 donor-specific MHC antigens,2 and
even autologous (recipient) MHC antigens.14 Our study
showed no difference in target lysis between the
cytomegalovirus+ and histologically normal groups
whereas there was a significant difference between tar-
get lysis, BEAS-2B sharing donor-mismatched class I
or II antigens, in the cytomegalovirus+ and acute rejec-
tion group. Notwithstanding the proliferative responses
of cytomegalovirus-primed BAL lymphocytes de-
scribed by other investigators,2,5,17 the CML assay sys-
tem we describe appears to distinguish reliably be-
tween acute rejection and cytomegalovirus infection
only when airway epithelial cell was used as a target.
We included K562 as a target in the panel to evaluate
the potential contribution of natural killer cells to lung
allograft rejection in vivo. Our data show that although
natural killer cell activity was evident in the BAL cell
population, it is unlikely that it plays an important role
in pulmonary allograft rejection, because there was no
significant difference in natural killer activity between
acute rejection, cytomegalovirus infection, and normal
activity. It is possible that the use of cyclosporine
masked the importance of these natural killer cells by
virtue of its potent inhibitory effects on interleukin-2
release. Further work would be necessary to clarify this
observation. 
In summary, donor class I–directed CTL activity is
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present in BAL lymphocytes from patients with lung
transplants who are undergoing acute rejection. The
activity is most apparent when the airway epithelial cell
is used as a target. These results suggest that a major
component of the immune response to lung allograft is
directed against the lung epithelium. These results may
have direct implications on the possible development
of chronic responses in these patients. Destruction of
the epithelium is a major pathologic feature in patients
with bronchiolitis obliterans syndrome. Our results
suggest that these changes may be immune mediated.
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